Literature DB >> 27729454

Ubiquitin-dependent Turnover of Adenosine Deaminase Acting on RNA 1 (ADAR1) Is Required for Efficient Antiviral Activity of Type I Interferon.

Lemin Li1, Guanghui Qian2, Yibo Zuo1, Yukang Yuan1, Qiao Cheng1, Tingting Guo1, Jin Liu1, Chang Liu1, Liting Zhang1, Hui Zheng3.   

Abstract

Adenosine deaminase acting on RNA 1 (ADAR1) catalyzes RNA editing of cellular and viral RNAs. Besides RNA editing, ADAR1 has recently been shown to play important roles in maintaining the body balance, including tissue homoeostasis, organ development, and autoimmune regulations, by inhibiting both IFN production and subsequent IFN-activated pathways. Accordingly, the question was raised how IFN signaling induced by viral infections overcomes the inhibitory effect of constitutively expressed ADAR1 (ADAR1-P110) to execute efficient antiviral activity. Here we unexpectedly found that IFN signaling promoted Lys48-linked ubiquitination and degradation of ADAR1-P110. Furthermore, we identified the E3 ligase β transducin repeat-containing protein responsible for IFN-mediated ADAR1-P110 down-regulation. IFN signaling promoted the interaction between β transducin repeat-containing protein and ADAR1-P110 as well as protein turnover of ADAR1-P110. Moreover, we found that both lysine 574 and 576 are essential for ADAR1-P110 ubiquitination. Critically, we demonstrated that down-regulation of ADAR1-P110 is required for IFN signaling to execute efficient antiviral activity during viral infections. These findings renew the understanding of the mechanisms by which IFN signaling acts to achieve antiviral functions and may provide potential targets for IFN-based antiviral therapy.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ADAR1; E3 ubiquitin ligase; antiviral immunity; innate immunity; interferon; protein degradation; ubiquitylation (ubiquitination)

Mesh:

Substances:

Year:  2016        PMID: 27729454      PMCID: PMC5122768          DOI: 10.1074/jbc.M116.737098

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  The novel functions of ubiquitination in signaling.

Authors:  Lijun Sun; Zhijian J Chen
Journal:  Curr Opin Cell Biol       Date:  2004-04       Impact factor: 8.382

2.  Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Authors:  Hui Zheng; Juan Qian; Christopher J Carbone; N Adrian Leu; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-10       Impact factor: 22.113

Review 3.  Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.

Authors:  Richard E Randall; Stephen Goodbourn
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

4.  Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.

Authors:  Hui Zheng; Juan Qian; Darren P Baker; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

Review 5.  ADAR1, inosine and the immune sensing system: distinguishing self from non-self.

Authors:  Brian J Liddicoat; Alistair M Chalk; Carl R Walkley
Journal:  Wiley Interdiscip Rev RNA       Date:  2015-12-21       Impact factor: 9.957

6.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 7.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.

Authors:  Charles E Samuel
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

8.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.

Authors:  Gillian I Rice; Paul R Kasher; Gabriella M A Forte; Niamh M Mannion; Sam M Greenwood; Marcin Szynkiewicz; Jonathan E Dickerson; Sanjeev S Bhaskar; Massimiliano Zampini; Tracy A Briggs; Emma M Jenkinson; Carlos A Bacino; Roberta Battini; Enrico Bertini; Paul A Brogan; Louise A Brueton; Marialuisa Carpanelli; Corinne De Laet; Pascale de Lonlay; Mireia del Toro; Isabelle Desguerre; Elisa Fazzi; Angels Garcia-Cazorla; Arvid Heiberg; Masakazu Kawaguchi; Ram Kumar; Jean-Pierre S-M Lin; Charles M Lourenco; Alison M Male; Wilson Marques; Cyril Mignot; Ivana Olivieri; Simona Orcesi; Prab Prabhakar; Magnhild Rasmussen; Robert A Robinson; Flore Rozenberg; Johanna L Schmidt; Katharina Steindl; Tiong Y Tan; William G van der Merwe; Adeline Vanderver; Grace Vassallo; Emma L Wakeling; Evangeline Wassmer; Elizabeth Whittaker; John H Livingston; Pierre Lebon; Tamio Suzuki; Paul J McLaughlin; Liam P Keegan; Mary A O'Connell; Simon C Lovell; Yanick J Crow
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

9.  RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment.

Authors:  Zhiqun Li; Karen C Wolff; Charles E Samuel
Journal:  Virology       Date:  2009-11-12       Impact factor: 3.616

10.  Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus.

Authors:  Ying Ren; Peng Zhao; Jin Liu; Yukang Yuan; Qiao Cheng; Yibo Zuo; Liping Qian; Chang Liu; Tingting Guo; Liting Zhang; Xiaofang Wang; Guanghui Qian; Lemin Li; Jun Ge; Jianfeng Dai; Sidong Xiong; Hui Zheng
Journal:  PLoS Pathog       Date:  2016-07-19       Impact factor: 6.823

View more
  14 in total

Review 1.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

2.  The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function.

Authors:  Praveen Koganti; Venkata Narasimha Kadali; Dhanoop Manikoth Ayyathan; Andrea Emanuelli; Biagio Paolini; Gal Levy-Cohen; Michael Blank
Journal:  Cell Mol Life Sci       Date:  2022-04-11       Impact factor: 9.261

Review 3.  How RNA modifications regulate the antiviral response.

Authors:  Matthew G Thompson; Matthew T Sacco; Stacy M Horner
Journal:  Immunol Rev       Date:  2021-08-17       Impact factor: 12.988

4.  Immunosuppressive lncRNA LINC00624 promotes tumor progression and therapy resistance through ADAR1 stabilization.

Authors:  Qi Zhang; Bingqiu Xiu; Liyi Zhang; Ming Chen; Weiru Chi; Lun Li; Rong Guo; Jingyan Xue; Benlong Yang; Xiaoyan Huang; Zhi-Ming Shao; Shenglin Huang; Yayun Chi; Jiong Wu
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

5.  Cutting Edge: Reduced Adenosine-to-Inosine Editing of Endogenous Alu RNAs in Severe COVID-19 Disease.

Authors:  Philip S Crooke; John T Tossberg; Krislyn P Porter; Thomas M Aune
Journal:  J Immunol       Date:  2021-03-29       Impact factor: 5.422

Review 6.  The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?

Authors:  Matthias R Schaefer
Journal:  Genes (Basel)       Date:  2021-02-26       Impact factor: 4.096

7.  Induction of OTUD1 by RNA viruses potently inhibits innate immune responses by promoting degradation of the MAVS/TRAF3/TRAF6 signalosome.

Authors:  Liting Zhang; Jin Liu; Liping Qian; Qian Feng; Xiaofang Wang; Yukang Yuan; Yibo Zuo; Qiao Cheng; Ying Miao; Tingting Guo; Xiaofeng Zheng; Hui Zheng
Journal:  PLoS Pathog       Date:  2018-05-07       Impact factor: 6.823

8.  β-TrCP Restricts Lipopolysaccharide (LPS)-Induced Activation of TRAF6-IKK Pathway Upstream of IκBα Signaling.

Authors:  Jin Liu; Yukang Yuan; Jing Xu; Kui Xiao; Ying Xu; Tingting Guo; Liting Zhang; Jun Wang; Hui Zheng
Journal:  Front Immunol       Date:  2018-12-13       Impact factor: 7.561

Review 9.  ADAR1: "Editor-in-Chief" of Cytoplasmic Innate Immunity.

Authors:  Mart M Lamers; Bernadette G van den Hoogen; Bart L Haagmans
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

10.  Ubiquitin E3 Ligase c-Cbl Is a Host Negative Regulator of Nef Protein of HIV-1.

Authors:  Hong-Guang Zhang; Jing Guo; Yukang Yuan; Yibo Zuo; Jin Liu; Li Zhu; Ying Miao; Xiangjie Chen; Lincong Jin; Fan Huang; Tengfei Ren; Jiuyi He; Weifeng Shi; Zhenke Wen; Chuanwu Zhu; Hui Zheng; Chunsheng Dong; Feng Qian
Journal:  Front Microbiol       Date:  2020-11-19       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.